Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating MIR-22 and BMP7

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Pofi, Riccardo ^a   Fiore, Daniela ^a   De Gaetano, Rita ^b   Panio, Giuseppe ^b   Gianfrilli, Daniele ^a   Pozza, Carlotta ^a   Barbagallo, Federica ^a   Xiang, Yang Kevin ^c   Giannakakis, Konstantinos ^b   Morano, Susanna ^a   Lenzi, Andrea ^a   Naro, Fabio ^b   Isidori, Andrea M ^a   Venneri, Mary Anna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINOID; BIOLOGICAL MARKER; BMP7 PROTEIN, MOUSE; CREATININE; MICRORNA; MIRN22 MICRORNA, MOUSE; OSTEOGENIC PROTEIN 1; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; UROKINASE RECEPTOR;

ANIMAL; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETIC NEPHROPATHY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; HYPERTENSION; KIDNEY; MALE; METABOLISM; MOUSE; PATHOLOGY; URINE;

ALBUMINS; ANIMALS; BIOMARKERS; BONE MORPHOGENETIC PROTEIN 7; CREATININE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DIABETIC NEPHROPATHIES; GENE EXPRESSION REGULATION; GLOMERULAR FILTRATION RATE; HEMODYNAMICS; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MICE; MICRORNAS; PHOSPHODIESTERASE 5 INHIBITORS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 85015220244     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep44584     Document Type: Article

References (50)

1. Atkins, R. C. & Zimmet, P. Diabetic kidney disease: act now or pay later. Kidney international 77, 375-377, doi: 10.1038/ki.2009.509 (2010).
2. Pofi, R. et al. Diabetic Nephropathy: Focus on Current and Future Therapeutic Strategies. Current drug metabolism 17, 497-502 (2016).
3. Reidy, K., Kang, H. M., Hostetter, T. & Susztak, K. Molecular mechanisms of diabetic kidney disease. The Journal of clinical investigation 124, 2333-2340, doi: 10.1172/jci72271 (2014).
4. Ingelfinger, J. R. & Rosen, C. J. Cardiac and Renovascular Complications in Type 2 Diabetes- Is There Hope? The New England journal of medicine, doi: 10.1056/NEJMe1607413 (2016).
5. Sharkovska, Y. et al. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. Journal of hypertension 32, 2211-2223, discussion 2223, doi: 10.1097/hjh.0000000000000328 (2014).
6. Dong, Y. F. et al. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. Journal of hypertension 28, 1554-1565, doi: 10.1097/HJH.0b013e328338bb11 (2010).
7. Andersen, H. et al. Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy. Journal of hypertension 34, 1621-1629, doi: 10.1097/hjh.0000000000000967 (2016).
8. Ruiz-Hurtado, G. & Ruilope, L. M. Salutary cardiovascular effects of antidiabetic drugs: myth or fact? Journal of hypertension 33, 2198-2199, doi: 10.1097/hjh.0000000000000741 (2015).
9. Versari, D., Daghini, E., Virdis, A., Ghiadoni, L. & Taddei, S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes care 32 Suppl 2, S314-321, doi: 10.2337/dc09-S330 (2009).
10. Dousa, T. P. Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney international 55, 29-62, doi: 10.1046/j.1523-1755.1999.00233.x (1999).
11. Craven, P. A., Studer, R. K. & DeRubertis, F. R. Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response. The Journal of clinical investigation 93, 311-320, doi: 10.1172/jci116961 (1994).
12. Giunti, S., Barit, D. & Cooper, M. E. Mechanisms of diabetic nephropathy: role of hypertension. Hypertension 48, 519-526, doi: 10.1161/01.HYP.0000240331.32352.0c (2006).
13. Brown, K. E., Dhaun, N., Goddard, J. & Webb, D. J. Potential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease. Hypertension 63, 5-11, doi: 10.1161/hypertensionaha.113.01774 (2014).
14. Jeong, K. H. et al. Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats. American journal of nephrology 29, 274-282, doi: 10.1159/000158635 (2009).
15. Kuno, Y., Iyoda, M., Shibata, T., Hirai, Y. & Akizawa, T. Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats. British journal of pharmacology 162, 1389-1400, doi: 10.1111/j.1476-5381.2010.01149.x (2011).
16. Fang, L. et al. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association- European Renal Association 28, 1751-1761, doi: 10.1093/ndt/gfs391 (2013).
17. Tripathi, A. S., Mazumder, P. M. & Chandewar, A. V. Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in STZ-induced diabetic rats. Journal of basic and clinical physiology and pharmacology 27, 57-62, doi: 10.1515/jbcpp-2015-0035 (2016).
18. Venneri, M. A. et al. Chronic Inhibition of PDE5 Limits Pro-Inflammatory Monocyte-Macrophage Polarization in Streptozotocin- Induced Diabetic Mice. PloS one 10, e0126580, doi: 10.1371/journal.pone.0126580 (2015).
19. Santi, D. et al. Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis. European journal of endocrinology/European Federation of Endocrine Societies 172, R103-114, doi: 10.1530/eje-14-0700 (2015).
20. Mandosi, E. et al. Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes. Expert opinion on therapeutic targets 19, 1617-1622, doi: 10.1517/14728222.2015.1066337 (2015).
21. Webb, D. J., Vachiery, J. L., Hwang, L. J. & Maurey, J. O. Sildenafil improves renal function in patients with pulmonary arterial hypertension. British journal of clinical pharmacology 80, 235-241, doi: 10.1111/bcp.12616 (2015).
22. Grover-Paez, F., Villegas Rivera, G. & Guillen Ortiz, R. Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. Diabetes research and clinical practice 78, 136-140, doi: 10.1016/j.diabres.2007.02.006 (2007).
23. Hamano, K., Nitta, A., Ohtake, T. & Kobayashi, S. Associations of renal vascular resistance with albuminuria and other macroangiopathy in type 2 diabetic patients. Diabetes care 31, 1853-1857, doi: 10.2337/dc08-0168 (2008).
24. MacIsaac, R. J. et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes care 29, 1560-1566, doi: 10.2337/dc05-1788 (2006).
25. Pontremoli, R. et al. Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association- European Renal Association 14, 360-365 (1999).
26. Brouwers, B. et al. Phlorizin pretreatment reduces acute renal toxicity in a mouse model for diabetic nephropathy. The Journal of biological chemistry 288, 27200-27207, doi: 10.1074/jbc.M113.469486 (2013).
27. De Palma, M., Venneri, M. A. & Naldini, L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Human gene therapy 14, 1193-1206, doi: 10.1089/104303403322168028 (2003).
28. Kelly, D. J., Buck, D., Cox, A. J., Zhang, Y. & Gilbert, R. E. Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. American journal of physiology. Renal physiology 293, F565-574, doi: 10.1152/ajprenal.00397.2006 (2007).
29. Zeisberg, M. et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nature medicine 9, 964-968, doi: 10.1038/nm888 (2003).
30. Long, J. et al. MicroRNA-22 is a master regulator of bone morphogenetic protein-7/6 homeostasis in the kidney. The Journal of biological chemistry 288, 36202-36214, doi: 10.1074/jbc.M113.498634 (2013).
31. Fiore, D. et al. PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial. The Journal of clinical endocrinology and metabolism 101, 1525-1534, doi: 10.1210/jc.2015-4252 (2016).
32. Giannetta, E. et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 125, 2323-2333, doi: 10.1161/ circulationaha.111.063412 (2012).
33. Guazzi, M., Vicenzi, M., Arena, R. & Guazzi, M. D. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circulation. Heart failure 4, 8-17, doi: 10.1161/circheartfailure.110.944694 (2011).
34. Giannetta, E. et al. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med 12, 185, doi: 10.1186/s12916-014-0185-3 (2014).
35. Dias, A. T. et al. Sildenafil ameliorates oxidative stress and DNA damage in the stenotic kidneys in mice with renovascular hypertension. Journal of translational medicine 12, 35, doi: 10.1186/1479-5876-12-35 (2014).
36. Rodriguez-Iturbe, B. et al. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney international 68, 2131-2142, doi: 10.1111/j.1523-1755.2005.00669.x (2005).
37. Scheele, W. et al. Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, doi: 10.1681/asn.2015050473 (2016).
38. Raij, L. & Baylis, C. Glomerular actions of nitric oxide. Kidney international 48, 20-32 (1995).
39. Fried, L. F. et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. The New England journal of medicine 369, 1892-1903, doi: 10.1056/NEJMoa1303154 (2013).
40. Hayek, S. S. et al. Soluble Urokinase Receptor and Chronic Kidney Disease. The New England journal of medicine 373, 1916-1925, doi: 10.1056/NEJMoa1506362 (2015).
41. Mancini, M. et al. Renal duplex sonographic evaluation of type 2 diabetic patients. Journal of ultrasound in medicine: official journal of the American Institute of Ultrasound in Medicine 32, 1033-1040, doi: 10.7863/ultra.32.6.1033 (2013).
42. Radermacher, J., Ellis, S. & Haller, H. Renal resistance index and progression of renal disease. Hypertension 39, 699-703 (2002).
43. Nosadini, R. et al. Increased renal arterial resistance predicts the course of renal function in type 2 diabetes with microalbuminuria. Diabetes 55, 234-239 (2006).
44. Parolini, C. et al. Renal resistive index and long-term outcome in chronic nephropathies. Radiology 252, 888-896, doi: 10.1148/ radiol.2523080351 (2009).
45. Ninet, S. et al. Doppler-based renal resistive index for prediction of renal dysfunction reversibility: A systematic review and metaanalysis. Journal of critical care 30, 629-635, doi: 10.1016/j.jcrc.2015.02.008 (2015).
46. Oliver, J. J., Melville, V. P. & Webb, D. J. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 48, 622-627, doi: 10.1161/01.HYP.0000239816.13007.c9 (2006).
47. Fahning, B. M. et al. Sildenafil Improves Vascular Endothelial Structure and Function in Renovascular Hypertension. Current pharmaceutical biotechnology 16, 823-831 (2015).
48. Wang, S. et al. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. Journal of the American Society of Nephrology: JASN 17, 2504-2512, doi: 10.1681/asn.2006030278 (2006).
49. Sugimoto, H., Grahovac, G., Zeisberg, M. & Kalluri, R. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 56, 1825-1833, doi: 10.2337/db06-1226 (2007).
50. Friese, R. S. et al. MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: functional and therapeutic implications for gene expression and the pathogenesis of hypertension. Human molecular genetics 22, 3624-3640, doi: 10.1093/hmg/ddt213 (2013).